ARTICLE | Financial News
J&J hits all-time high on earnings news
July 19, 2016 7:00 AM UTC
Johnson & Johnson (NYSE:JNJ) gained $2.11 to $125.25 on Tuesday, touching an intraday all-time high of $125.75, after it reported 2Q16 financial results that beat analyst estimates and raised its 2016 guidances. The pharma's 2Q16 worldwide pharmaceutical sales were $8.65 billion, up 8.9% from $7.95 billion in 2Q15. Its adjusted EPS was $1.74 per share, up from $1.71 in 2Q15 and ahead of the consensus $1.68 estimate.
Worldwide 2Q16 sales of leukemia drug Imbruvica ibrutinib were $295 million, up from $154 million in 2Q15. The pharma holds ex-U.S. rights to Imbruvica from AbbVie Inc. (NYSE:ABBV). The partners share the drug's U.S. rights. ...